Medopad rebrands to Huma, makes acquisitions to bolster its AI health monitoring portfolio

Digital health company Medopad today announced that it's rebranding to Huma and acquiring two companies -- BioBeats and Tarilian Laser Technologies (TLT) -- to add support for new biomarkers to its AI-powered patient monitoring platform. When contacted for comment, a Huma spokesperson declined to disclose the purchase price for the two companies. The acquisitions would appear to be strategic -- increasingly, health systems and hospitals are employing AI-enabled telemedical services to triage and treat patients potentially infected with COVID-19. Huma previously leveraged AI to identify signs of chronic diseases like Parkinson's disease, in partnership with Tencent, but the incorporation of BioBeats' and TLT's technologies will enable it to analyze mental and cardiovascular health data. The thinking goes that the more holistic Huma's platform becomes, the better health outcomes are likely to be.